- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:34 | listed ImmuneOnco Biopharma slumps on discounted share sale | 1 | Reuters | ||
| Mi | IMMUNEONCO-B (01541): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| Mo | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM0306 | 1 | HKEx | ||
| 13.11. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM27M | - | HKEx | ||
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.11. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE ... | - | HKEx | ||
| 25.10. | IMMUNEONCO-B (01541): INSIDE INFORMATION - PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PROGRAMME BY THE COMPANY | - | HKEx | ||
| 24.10. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF SLE | 1 | HKEx | ||
| 14.10. | IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 14.10. | IMMUNEONCO-B (01541): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 30.09. | IMMUNEONCO-B (01541): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.09. | IMMUNEONCO-B (01541): (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 27.09. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTION - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT | - | HKEx | ||
| 23.09. | IMMUNEONCO-B (01541): 2024 INTERIM REPORT | - | HKEx | ||
| 16.09. | Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer | 106 | GlobeNewswire (Europe) | Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line triple-negative breast cancer (TNBC)Initiation... ► Artikel lesen | |
| 16.09. | IMMUNEONCO-B (01541): INSIDE INFORMATION - UPDATE ON GLOBAL REGISTRATIONAL STRATEGY FOR IMM2510 FOR NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST ... | 1 | HKEx | ||
| 13.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - TRANSFER OF EQUITY INTEREST IN A SUBSIDIARY | - | HKEx | ||
| 11.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M | 1 | HKEx | ||
| 10.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS | 2 | HKEx | ||
| 04.09. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 04.09. | IMMUNEONCO-B (01541): INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,220 | +3,55 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| EVOTEC | 10,070 | +1,67 % | BASF, Evotec, GFT, Knaus Tabbert, LVMH, Wienerberger - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,580 | -3,68 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| IMMUNOVANT | 26,540 | +1,34 % | Immunovant stock hits 52-week low at $24.66 amid market shifts | ||
| BIONTECH | 103,40 | +6,65 % | Das Übernahme-Karussell kommt in Schwung! Evotec, Vidac Pharma, BioNTech und Formycon im Fokus | Der Sektor BioTech steht heute erneut im Fokus. Mit dem Triton-Einstieg bei Evotec ist wieder ein Deal am Laufen, Investoren sollten nun hellhörig werden. Viele erinnern sich noch an MorphoSys, hier... ► Artikel lesen | |
| KEROS THERAPEUTICS | 53,84 | -0,46 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| JANUX THERAPEUTICS | 46,500 | -5,04 % | Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,755 | -4,72 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| GALAPAGOS NV | 24,000 | -0,17 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| AVIDITY BIOSCIENCES | 42,530 | -2,59 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,78 | +0,03 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| BB BIOTECH | 38,650 | 0,00 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| NUVALENT | 92,65 | +1,55 % | Nuvalent-CEO Porter verkauft Aktien im Wert von 2,37 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 36,300 | -3,04 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| ARCTURUS THERAPEUTICS | 17,070 | +5,44 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen |
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,125 (-12,82 %) liegt der Kurs bei 0,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.
